<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792584</url>
  </required_header>
  <id_info>
    <org_study_id>08-136</org_study_id>
    <nct_id>NCT00792584</nct_id>
  </id_info>
  <brief_title>Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz</brief_title>
  <acronym>SWITCH-EE</acronym>
  <official_title>Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Lugano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Neuch√¢tel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efavirenz causes neuropsychiatric side effects and sleep disturbance, including vivid dreams,
      dizziness, and abnormal tiredness. These symptoms are frequent during the first weeks of
      treatment, with subsequent attenuation but may not completely resolve even years after
      efavirenz initiation.

      The investigators plan a twelve week, randomized, placebo-controlled, double-blind study. In
      group 1, efavirenz will be replaced with efavirenz placebo plus etravirine, in group 2,
      efavirenz would be continued, and etravirine placebo given in addition. After six weeks,
      patients in group 1 would switch to the regimen of group 2, and vice versa.

      The primary endpoint of the trial will be patient preference. Sleep quality, daytime
      sleepiness, and anxiety will also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms and neurological side effects of study drugs</measure>
    <time_frame>baseline, week 6 and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of daytime sleepiness</measure>
    <time_frame>baseline, week 6 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>baseline, week 6 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression, anxiety and stress will be assessed</measure>
    <time_frame>baseline, week 6 and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treats with etravirine for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treats with efavirenz for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etravirine</intervention_name>
    <description>Patient receives etravirine/ placebo or efavirenz / placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>patient receives efavirenz / placebo or etravirine / placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years

          -  Signing the study consent form and agree to change ART regimen

          -  Stable HAART including EFV since at least 3 months

          -  HIV-RNA below 50 copies for at least 3 months

        Exclusion Criteria:

          -  No major psychiatric disease (psychosis, severe depression) diagnosed before the
             initiation of EFV

          -  Mentally incompetent patients

          -  Pregnancy or lactation Women of childbearing potential must use one or two reliable
             contraceptive methods during the trial, from day 1 to the end of week 12. Acceptable
             methods include the birth control pill, IUD, condoms with spermicides. Non-acceptable
             methods include (non-exhaustive list): Withdrawal, calendar (Onigo method), or
             spermicides alone.

          -  Concomitant renal or hepatic disease:

               -  Creatinine above 150 micromol/L

               -  Transaminases above 5 times upper normal limit

               -  Prothrombin (Quick) value below 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard BH Hirschel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geneva Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geneva Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.shcs.ch</url>
    <description>Swiss HIV Cohort Study</description>
  </link>
  <link>
    <url>http://www.doctorswiss.ch/bernard-hirschel/</url>
    <description>Homepage Bernard Hirschel</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2008</study_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Alain Nguyen, Dr</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>etravirine</keyword>
  <keyword>efavirenz</keyword>
  <keyword>anxiety</keyword>
  <keyword>depression</keyword>
  <keyword>sleep quality</keyword>
  <keyword>HIV</keyword>
  <keyword>NNRTI</keyword>
  <keyword>Tritherapy</keyword>
  <keyword>compliance</keyword>
  <keyword>stocrin</keyword>
  <keyword>To replace efavirenz in long-term users with etravirine</keyword>
  <keyword>To investigate effect of such replacement on patient preference, sleep quality, daytime sleepiness, and anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

